StockData

Cardiff Oncology vs Exicure

CRDF and XCUR side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRDF and XCUR compare

Cardiff Oncology is the larger company, worth 9.6 times as much as Exicure ($65.3M against $6.8M).

Cardiff Oncology scores higher on the StockData Score (7 against 4 for Exicure), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRDFXCUR
Size and price
Market cap$65.3M$6.8M
Share price$0.839$1.04
Change, 1 year−59.3%−71.3%
Change, 5 years−85.0%−98.6%
Beta (5Y)1.581.27
Employees318
StockData Score
Total score7 (better)4
Valuation score00
Growth score1 (better)0
Performance score1 (better)0
Health score5 (better)4
Dividend score00
Valuation
P/S128×–
P/B2.5× (better)7.0×
Growth
Revenue growth (TTM)−7.0%–
Revenue growth, 5Y average10.1%–
Profitability
Operating margin−8320%–
Net margin−7884%–
Return on equity−94.1% (better)−168%
Return on invested capital–−4377%
Financial health
Debt / equity0.000.00
Current ratio3.30 (better)0.56
Altman Z-score−16.24 (better)−27.38
Piotroski F-score12 (better)
Dividends and buybacks
Buyback yield–0.00%
Shareholder yield0.00%0.00%
Ownership
Held by institutions24.2%2.1%
Held by insiders4.9%92.6%
Insider net buying, 12 months$1.1M (better)−$11.6M
Short interest, % of float16.6%10.8%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.